83 Clemenceau Avenue #12-03 UE Square

Singapore 239920


April 30, 2018

U.S. Securities and Exchange Commission

Office of Healthcare and Insurance

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn: Ms. Irene Paik

Mr. Christopher Edwards


Re: ASLAN Pharmaceuticals Limited

Registration Statement on Form F-1

File No. 333-223920


  Acceleration Request   
                Requested Date:    Wednesday, May 2, 2018
                Requested Time:    4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 to become effective on May 2, 2018, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Robert Phillips and Charles Kim of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Phillips of Cooley LLP at (415) 693-2020, or in his absence, Charles Kim at (858) 550-6049. Thank you for your assistance with this matter.

ASLAN Pharmaceuticals Limited
By:   /s/ Carl Firth
  Carl Firth, Ph.D.
  Chief Executive Officer and Chairman


cc:   Kiran Asarpota, ASLAN Pharmaceuticals Limited
  Robert W. Phillips, Cooley LLP
  Sean M. Clayton, Cooley LLP
  Charles S. Kim, Cooley LLP
  Patrick Loofbourrow, Cooley LLP
  Alan F. Denenberg, Davis Polk & Wardwell LLP